干扰素基因蛋白刺激物 (STING) 可激活炎症细胞中的免疫反应。癌细胞中的 STING 表达尚不清楚，但目前正在评估 STING 激动剂作为抗癌药物的作用。通过免疫组织化学对包含来自 139 种不同肿瘤类型的 18,001 个样本的组织微阵列进行 STING 分析。在 139 个肿瘤实体中的 130 个（93.5%）中发现了 STING 阳性肿瘤细胞。 STING 阳性率最高的是鳞状细胞癌（高达 96%）；恶性间皮瘤（88.5%-95.7%）；胰腺腺癌（94.9%）、肺腺癌（90.3%）、子宫颈腺癌（90.0%）、结直肠腺癌（75.2%）和胆囊腺癌（68.8%）；和浆液性高级别卵巢癌（86.0%）。 STING 高表达与乳腺癌、透明细胞肾细胞癌、结直肠腺癌、肝细胞癌和甲状腺乳头状癌的不良表型相关 (p < 0.05)。在 pTa 尿路上皮癌中，STING 表达与低级别癌相关 (p = 0.0002)。在所有肿瘤中，STING 表达与肿瘤细胞和炎症细胞的 PD-L1 阳性率平行（p < 0.0001），但与 CD8 淋巴细胞的密度无关。 STING 表达在不同肿瘤类型中存在差异，可能与侵袭性肿瘤表型和 PD-L1 阳性相关。与肿瘤浸润 CD8 淋巴细胞缺乏关系，这反驳了 STING 阳性肿瘤细胞产生显着 IFN 的观点。

Stimulator of interferon genes protein (STING) activates the immune response in inflammatory cells. STING expression in cancer cells is less well characterized, but STING agonists are currently being evaluated as anticancer drugs. A tissue microarray containing 18,001 samples from 139 different tumor types was analyzed for STING by immunohistochemistry. STING-positive tumor cells were found in 130 (93.5%) of 139 tumor entities. The highest STING positivity rates occurred in squamous cell carcinomas (up to 96%); malignant mesothelioma (88.5%-95.7%); adenocarcinoma of the pancreas (94.9%), lung (90.3%), cervix (90.0%), colorectum (75.2%), and gallbladder (68.8%); and serous high-grade ovarian cancer (86.0%). High STING expression was linked to adverse phenotypes in breast cancer, clear cell renal cell carcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, and papillary carcinoma of the thyroid (p < 0.05). In pTa urothelial carcinomas, STING expression was associated with low-grade carcinoma (p = 0.0002). Across all tumors, STING expression paralleled PD-L1 positivity of tumor and inflammatory cells (p < 0.0001 each) but was unrelated to the density of CD8+ lymphocytes. STING expression is variable across tumor types and may be related to aggressive tumor phenotype and PD-L1 positivity. The lack of relationship with tumor-infiltrating CD8+ lymphocytes argues against a significant IFN production by STING positive tumor cells.